marketshareAI
Theme

GSK

GSKHealthcare
1,784.00GBX
-0.22%
Market Cap
71.66B
Volume
228.8k
3% of avg
P/E Ratio
1061.90
EPS (TTM)
1.68
Beta
0.23
Day Range
1,780.50p - 1,793.50p
52 Week Range
1,242.50p1,784.00p1,830.00p
1,784.00p

Upcoming Events

December 2025
US decision on depemokimab for asthma
High Impact Event
December 2025
Potential Regulatory Approval
High Impact Event
December 16, 2025
PDUFA date for FDA review of depemokimab submissions
High Impact Event
Q4 2025
GSK plans to file tebipenem HBr data with US regulators
High Impact Event
1 January 2026
Luke Miels assumes full CEO responsibilities
High Impact Event
Early Q1 2026
Expected regulatory decision on Arexvy for adults 18 years and older
High Impact Event
2026
Launch of next-generation low carbon Ventolin MDI
High Impact Event
24 March 2026
PDUFA goal date for FDA decision on linerixibat NDA
High Impact Event
30 September 2026
Emma Walmsley's employment with GSK ends
2029
Potential first launch of efimosfermin
High Impact Event
Beyond 2031
Significant new growth opportunities for GSK
High Impact Event
2034
End of extended exclusive rights for Zhifei to commercialize Shingrix in China
High Impact Event
GSK
GOOD

GSK Initiates Litigation Against AnaptysBio Over Jemperli Licence

The healthcare company has initiated legal action against a partner over a key oncology treatment, potentially impacting the commercial terms of the agreement.

GSK
NEUTRAL

GSK Announces Director/PDMR Shareholding

The pharmaceutical company has announced changes to director and PDMR shareholdings through dividend reinvestment.

GSK
NEUTRAL

GSK Directors Acquire Shares Under Reward Plan

The major pharmaceutical company's directors have acquired ordinary shares under the company's employee share plan.

GSK
NEUTRAL

GSK Announces Director/PDMR Shareholding Transactions

The healthcare company has disclosed transactions involving the sale of ordinary shares by two senior executives.

GSK
VERY GOOD

GSK Delivers Strong Q3 Performance and Upgrades 2025 Guidance

The healthcare company reports strong Q3 results, upgrading its 2025 guidance for turnover, core operating profit and core EPS growth.

GSK
NEUTRAL

GSK's Antibody-Drug Conjugate Receives Orphan Drug Designation in EU

The healthcare company's new antibody-drug conjugate has received a regulatory designation in Europe, supporting its development in a rare form of lung cancer.

GSK
NEUTRAL

No mandatory news type found in RNS

The RNS announcement does not contain any of the required news types for analysis.

GSK
NEUTRAL

GSK announces positive data for low carbon Ventolin MDI

The healthcare company has announced positive data for a low carbon version of its Ventolin metered dose inhaler, which could reduce greenhouse gas emissions by 92% per inhaler.

GSK
NEUTRAL

GSK provides update on latozinemab trial

The pharmaceutical company has reported results from a clinical trial of its latozinemab drug, which did not meet the primary endpoint.

GSK
NEUTRAL

GSK's Shingrix Vaccine Gets Positive CHMP Opinion for Prefilled Syringe

The healthcare company received a positive opinion from the European regulator for a new prefilled syringe version of its shingles vaccine Shingrix.